Cipla Limited, a global pharmaceutical company, has launched an artificial intelligence-powered initiative called “Breathefree 90” in Nepal to support patients with chronic respiratory conditions.

The programme, developed in collaboration with the Nepal Respiratory Society, seeks to improve inhaler adherence through personalised daily reminders and educational support.

The three-month initiative uses a WhatsApp-based chatbot to send patients reminders to take their inhaler medication consistently, along with tips on correct usage and disease management. It is aimed at patients with asthma and chronic obstructive pulmonary disease (COPD), illnesses that are increasingly common in Nepal due to worsening air pollution. According to health estimates, air pollution contributes to around 50,000 deaths annually in the country.

Despite the availability of effective inhaler-based therapies, poor adherence to treatment regimens remains a major barrier to better health outcomes. Cipla’s initiative is designed to address this challenge by making it easier for patients to follow their prescribed treatment plans, the company said.

Patients can enrol in the programme by scanning a QR code displayed in hospitals, clinics and pharmacies. Once enrolled, they receive interactive, customised messages through WhatsApp based on their treatment schedules. Participation requires patient consent.

“This programme reflects our commitment to using next-generation technology to improve how people live with chronic respiratory conditions,” said Swapn Malpani, CEO of Emerging Markets and Europe at Cipla. “Breathefree 90 is a big step in that direction.”

The Nepal Respiratory Society will support the rollout by encouraging healthcare professionals to adopt the programme in clinical settings and help raise awareness among patients.